Druggability & Clinical Context
Druggability
Low
Score: 0.30
Druggability Analysis
Structural Tractability0.30
Key Metrics
PDB Structures:
0
Known Drugs:
2
Approved:
0
In Clinical Trials:
0
Drug Pipeline (2 compounds)
2 Preclinical
Druggability Rationale: GPR37 presents moderate druggability (0.60 score) as a GPCR with established G-protein coupling mechanisms and validated neuroprotective function, supported by investigational ligands like Prosaposin demonstrating target engagement. However, the lack of crystal structures (0 PDB entries), orphan receptor status with limited endogenous ligand characterization, and absence of cryo-EM data present significant challenges in rational drug design and binding site optimization.
Mechanism: GPR37 agonists or modulators would activate the receptor to promote dopaminergic neuron survival and neuroprotection, counteracting the neurodegeneration characteristic of Parkinson's disease. Ligands binding to GPR37 would enhance G-protein signaling cascades that support neuronal viability and function.
Drug Pipeline (2 compounds)
2 Preclinical
Known Drugs:Prosaposin (investigational) — Endogenous neuroprotective ligand for GPR37
TX14(A) (preclinical) — Prosaptide, GPR37 agonist peptide
Structural Data:PDB —AlphaFold ✓Cryo-EM —
Selectivity & Safety Considerations
GPR37 selectivity against other orphan GPCRs and related family members (GPR37L1) represents a key challenge, as sequence homology among GPCRs often leads to off-target activity. The lack of structural templates necessitates empirical selectivity screening, though the neuroprotection-specific phenotype may provide some therapeutic window if peripheral GPCR activation is minimized.
Clinical Trials (10)
Relevant trials from ClinicalTrials.gov
By Phase
NA: 1 · PHASE1: 2 · PHASE2: 1 · PHASE3: 2 · PHASE4: 1 · Unknown: 3
Unknown
NCT03415984
n=133
Parkinson Disease, Age Related Macular Degeneration
Interventions: Color retinography, Optical coherence tomography, Fundus autofluorescence imaging
Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Started: 2018-01-19
PHASE1
NCT04050553
n=42
Diabetes Mellitus, Type 2, Hypoglycemia
Interventions: Tirzepatide, Placebo
Sponsor: Eli Lilly and Company | Started: 2020-02-24
PHASE2
NCT06727331
n=20
Alcohol Use Disorder (AUD)
Interventions: Tirzepatide, Saline Placebo
Sponsor: Brigham and Women's Hospital | Started: 2025-09-15
NA
NCT06301256
n=20
Hidradenitis Suppurativa
Interventions: TIRZEPATIDE
Sponsor: Florida Academic Centers Research and Education, LLC | Started: 2024-03-11
PHASE1
NCT04235959
n=24
Diabetes Mellitus, Type 2
Interventions: Tirzepatide, Placebo
Sponsor: Eli Lilly and Company | Started: 2020-10-21
PHASE4
NCT06803888
n=125
Obesity and Obesity-related Medical Cond
Interventions: Bariatric Surgery, Semaglutide, Tirzepatide
Sponsor: Ali Aminian | Started: 2025-01-29
Unknown
NCT00855296
n=69
Coronary Artery Disease, Acute Coronary Syndrome
Sponsor: Vanderbilt University | Started: 2006-09
PHASE3
NCT06962280
n=465
Type 1 Diabetes, Obesity, Overweight
Interventions: Tirzepatide, Placebo
Sponsor: Eli Lilly and Company | Started: 2025-05-12